Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
At a glance
- Drugs Cyclophosphamide (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Mar 2017 Status changed from completed to discontinued as Primary Endpoint not met.
- 07 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.